Introduction to Versus 3

Versus 3 - 2% versus 32. ^[1] 0% versus 36. ^[2] 0 versus 30. ^[3] No significant difference was noted in the prevalence of ASCVD in Black versus EA patients with familial hypercholesterolemia (39% versus 32%, respectively; P=0. ^[4] Anterior TNs with EPE were more likely to exhibit SM+ than posterior TNs with EPE (62% versus 30. ^[5] Bambuti were more dependent on wild meat for survival (51% versus 32% of controls, p = 0. ^[6] 57%) versus 38 (2. ^[7] 1% versus 3. ^[8] parainfluenzae (73% versus 30%, P = 0. ^[9] More providers took over 60 minutes to complete medical documentation without the use of a scribe pre-pandemic (72% versus 30% with a scribe, P = 0. ^[10] 2% versus 31. ^[11] 8% versus 3. ^[12] 05) and daytime dozing (57% versus 35%; OR = 1. ^[13] Immediate access-related complications were significantly higher with femoral than carotid artery access; 9 (45%) versus 3 (15%) respectively, p = 0. ^[14] 6% versus 3. ^[15] 1% versus 3. ^[16] 001), lower LVEF (29 ± 9% versus 36 ± 13%, P = 0. ^[17] 2% versus 37. ^[18] Nephrographic ALAD was able to differentiate malignant pathology from oncocytoma in the training and validation cohorts with a sensitivity of 84% versus 73%, specificity of 86% and 67%, PPV of 98% versus 91%, and NPV of 33% versus 35%. ^[19] 003), percentage of men [7/8 patients (88%) versus 3/12 patients (25%), P = 0. ^[20] 01), cough (71% versus 38%, P = 0. ^[21] 0% versus 31. ^[22] 66% versus 3. ^[23] 5) versus 33. ^[24] Results In 65% (Automated) and 45% (Landmark) of cases, either inclination or version varied by 5° or more versus 3D printed scapula. ^[25] 89) versus 3. ^[26] After adjustment for covariates, prestroke disability was not associated with a lower chance of achieving favorable outcome at 90 days (24% versus 30%; odds ratio, 0. ^[27] 1% versus 37. ^[28] 7% versus 30. ^[29] 6% versus 36. ^[30] 2% versus 35. ^[31] 5% versus 32. ^[32] Overall, injuries from ASW had a higher injury severity score, but more procedures were performed on SISWs (46% versus 34%, P < 0. ^[33] 1% versus 30. ^[34] 0 versus 34. ^[35] 30%) versus 39 (51. ^[36] 4% versus 31% in HIDAC and IDAC groups respectively (p = 0. ^[37] 2) versus 324. ^[38] 001) and have significantly higher frequency of atherosclerotic disease (64 % versus 36 %, p<0. ^[39] RESULTS We found fewer serious complications with biosynthetic mesh: 21% versus 33% with biologic mesh. ^[40] 3% versus 3132. ^[41] 75% versus 3. ^[42] 8% (49/2767) versus 3. ^[43] 7% versus 33. ^[44] 04 and 67% versus 37%; p =. ^[45] 5%) versus 35% (n7/20) in surgery group. ^[46] We compared the hematological and renal toxicity profile between the weekly cisplatin (30 mg/m) (group A) versus 3-weekly (100 mg/m2) (group B) dosage schedule in this setting. ^[47] During follow-up in Group A, a biliary fistula was found in 2 patients (1 %) versus 3 patients in the Group B (2,6 %). ^[48] 6% versus 37. ^[49] 1% (Tendril) versus 3. ^[50]

% 95 %

RESULTS Actuarial 5-year symptomatic perineal hernia rates were 7% (95% CI, 0-30) after biological mesh closure versus 30% (95% CI, 10-49) after primary closure (P = 0. ^[1] 50]) with pooled three-year OS rates of 86% (95% CI, 82-90%) versus 39% (95% CI, 24-54%). ^[2] None of patients in the study group required reoperation for non-surgical bleeding versus 3 (4%, 95% CI -0. ^[3] The rate of acute graft-versus-host disease at 100 days was 41% (95% CI [21–55%]) in cryopreserved group versus 31% (95% CI [13–46%]) in fresh group (P = 0. ^[4] By laser, the closure rate was 96% (95% CI [87 ~ 100%]), the VA improved in 73% (95% CI [65 ~ 80%]) of the patients, and the VA of 66% (95% CI [47 ~ 84%]) hemorrhagic versus 35% (95% CI [23 ~ 47%]) exudative patients improved significantly. ^[5] Among the patients with grade II-IV aGVHD, the rate of steroid-refractory aGVHD was 9% (95% confidence interval [CI], 5% to 18%) in the BM group versus 32% (95% CI, 19% to 54%) in the PB group (hazard ratio [HR], 3. ^[6] In the per-protocol analysis, thoracic ultrasonography-guided care was non-inferior to standard care in terms of pleurodesis failure at 3 months, which occurred in 27 (29·7%) of 91 patients in the intervention group versus 34 (31·2%) of 109 patients in the standard care group (risk difference -1·5% [95% CI -10·2% to 7·2%]; non-inferiority margin 15%). ^[7] For Black versus White women, tubal infertility was twice as common with, 7% (95% confidence interval, 1–30%) starting in vitro fertilization versus 31% (95% confidence interval, 17–49%). ^[8] Compared to MSMW who recently had sex with both men and women, MSMW who recently had sex with men only were more likely to have had a recent HIV test (57%, 95% CI: 49–68 versus 30%, 95% CI: 21–39) and a recent STD test (55%, 95% CI: 46–64 versus 45%, 95% CI: 35–55). ^[9] 5 months, complete remission was 79% (95% CI 63% to 90%) in the decitabine-plus-camrelizumab group versus 32% (95% CI 13% to 57%) in the camrelizumab group (p=0. ^[10]

progression free survival

In the intention-to-treat analysis, after a median follow-up of 75 months, 5-year progression-free survival was 66% in MRD-negative versus 31% in MRD-positive patients (HR 0. ^[1] Regarding the outcomes to CII, no significant differences were reported in overall response rate (ORR), disease control rate (DCR), progression free survival (PFS) or overall survival (OS) (42% versus 37%, 60% versus 59%, 12 (95% CI, 7–18) versus 9 months (95% CI, 6–16) and 32 (95% CI, 23–49) versus 27 months (95% CI, 16–35), respectively). ^[2] At a median follow-up of 56·2 months (IQR 52·7-59·9), median progression-free survival was not reached (95% CI 54·8-not reached) in the daratumumab group versus 34·4 months (29·6-39·2) in the control group (hazard ratio [HR] 0·53 [95% CI 0·43-0·66]; p<0·0001). ^[3] Survival outcomes were better in the combined treatment group than in the TACE-alone group: the median progression-free survival for PVBTT was 9 months versus 3 months (HR = 0. ^[4] Progression-free survival was similar for IMDC 2 versus 3 (p = 0. ^[5] Following concurrent SRS and immunotherapy, patients had a significantly longer period of intracranial progression free survival than those treated with nonconcurrent therapy, 19 months versus 3. ^[6]

statistically significant difference

There was no statistically significant difference in the mean age at T1D diagnosis (16 and 27 years), mean duration of T1D at questionnaire (22 and 30 years), white non-Hispanic ethnicity (1906/2138, 89% versus 30/33, 91%), private insurance (1509/2138, 79% versus 30/33, 91%), and annual household income in US dollars ≥ $100 000 (757/2138, 45% versus 16/33, 55%) in the fertile and infertile men, respectively. ^[1] There were few clinically or statistically significant differences in the prevalence or severity of symptoms by hospitalization status (median (interquartile range) of total symptom score 39 (28-56) in hospitalized versus 32 (20-47) in hospitalized patients, p-value=0. ^[2] At 12 months, there was no statistically significant difference in the cumulative incidence of treatment failure for any reason between lamotrigine and lacosamide: 38% (95%CI 26–51%) versus 30% (95%CI 20–41%), respectively. ^[3] However, statistically significant differences were noted in the use of condoms (13% versus 3%, p=0. ^[4] When the clinical correlation of the findings was examined, a statistically significant difference was found in the Japanese Orthopedic Association scores and visual analog scale scores of the patients measured preoperatively versus 3 months postoperatively (p < 0. ^[5] A statistically significant difference was found between the final elastography scores of the patient and control groups, mean values being 4,16 ± 0,75 versus 3,08 ±0,40 respectively (p<0. ^[6]

versus 43 %

The difference between knowledge and practice was 80% versus 43% for TB and 55% versus 37% for HIV, resulting in know-do gaps of 37% (95% CI 19% to 55%) and 18% (95% CI −1% to 38%), respectively. ^[1] Typhimurium, twofold resistance levels were observed to streptomycin (97 versus 43%), ampicillin (80 versus 40%) and tetracyclines (67 versus 36%). ^[2] Invasive ventilation was required in seven of 17 children (41%) with pediatric inflammatory multisystem syndrome temporally associated with severe acute respiratory syndrome coronavirus-2 versus 38 of 56 other severe acute respiratory syndrome coronavirus-2 positive children (68%), with 77% requiring vasoactive support versus 43%, respectively. ^[3] Follow-up surveys demonstrated more respondents found questions “completely relevant” (34% pre versus 43% post) but perceived increased work burden (26% pre versus 31% post). ^[4]

hazard ratio 0

RESULTS PAM with Cal/BD foam was associated with longer median time to first relapse (111 versus 31 days), reduced risk of first relapse (hazard ratio: 0. ^[1] In participants with CKD, apabetalone compared with placebo was associated with fewer major adverse cardiovascular events (13 events in 124 patients [11%] versus 35 events in 164 patients [21%]; hazard ratio, 0. ^[2] Recurrence-free survival was 401 of 853 [47%] for patients who had combined epidural–general anesthesia versus 389 of 859 [45%] with general anesthesia alone: adjusted hazard ratio, 0. ^[3]

% versus 23

In comparison with d-dimer alone, the random forest model showed 68% versus 32% specificity at 95% sensitivity, and 44% versus 23% sensitivity at 95% specificity. ^[1] 001) and computerized tomography scans performed prior to transfer (Head 47% versus 32%, C-spine 36% versus 23%, Thorax 22% versus 16%, Abdomen/Pelvis 24% versus 14%, all P values <0. ^[2] Results Self-reported swallowing dysfunction and clinical signs thereof were more common in COPD patients than in the control group (67% versus 23% and 80% versus 37%, respectively; p≤0. ^[3]

% versus 60

Probands with concordant RFDRs had more pronounced changes: high activity (56% versus 32%), X-ray erosive stages (67% versus 60%) and stages III and IV (32% versus 6%); FC3 and FC4 (23% versus 12%) and a tendency towards more frequent development of the late clinical stage (11% versus 2%). ^[1] Mortality was significantly lower in RR/MDR-TBM patients on linezolid-containing treatment regimen than those who were not (0/7 versus 3/5, 0% versus 60%, P = 0. ^[2] Significantly more OCTR patients filled perioperative prescriptions (62% versus 60%), and the OCTR group filled higher quantities of perioperative opioids (411 OME versus 379 OME). ^[3]

intensive care unit

Patients with seizures had significantly a longer median intensive care unit length of stay, (43 versus 32 days, p = 0. ^[1] 9 days), were more likely to have a tracheostomy (55% versus 33%), and had a longer stay in the intensive care unit (+8. ^[2] 76 hours), had higher postoperative 0th -day total mobilization time (128 minutes versus 34 minutes), had a shorter passage of flatus time and length of intensive care unit and hospital stay and had higher sleep quality and satisfaction scores. ^[3]

% versus 59

Results: More patients received instructions for RTP (87% versus 59%) and RTL (60% versus 3%), and a complete discharge was more frequent (45% versus 2%), following the conclusion of the intervention. ^[1] We analyzed 132 meningiomas: 73 non-skull base (55%) versus 59 skull base (45%), 93 symptomatic (70%) versus 39 asymptomatic (30%). ^[2] De-escalation was attempted in 62% versus 34% in 2016, oral medication offered first in 71% versus 59% in 2016. ^[3]

versus 28 %

More respondents agreed than disagreed that trial eligibility criteria are too restrictive (48% agreed versus 28% disagreed), that screening assessments generally have unnecessary tests (51% versus 23%), that physical examination should only be performed when clinically indicated (43% versus 30%), that electronic patient outcomes/questionnaires are better at detecting adverse events that a consultation with a study doctor (33% versus 29%), that wearable technology/validated tools for patients to perform self-examination would provide more useful information than vital sign assessment in the study center (48% versus 13%), and that replacing routine in person visits with virtual visits would not significantly compromise patient safety (36% versus 28%). ^[1] Men were more often exposed than women to occupational risk factors (63% of men versus 28% of women) such as solvents and ambient heat, and women were more often exposed than men to poor indoor air quality and volatile organic compounds (49% of women versus 30% of men). ^[2] Among the 3 cohorts (CSWG‐MI versus DDR versus CSWG‐HF), in‐hospital mortality was 21% versus 28% versus 10%, 45% versus 40% versus 32%, and 55% versus 56% versus 52% for clusters I, II, and III, respectively. ^[3]

adjusted odds ratio

Radiotherapy did not reduce dysphagia deterioration, which was reported in 36 (49%) of 74 patients receiving usual care versus 34 (45%) of 75 receiving EBRT (adjusted odds ratio 0·82 [95% CI 0·40–1·68], p=0·59) in those with complete data for the primary endpoint. ^[1] Women who received obstetric care after implementation were significantly more likely than those who received care before implementation to receive antenatal screening for depression (81% versus 33%; adjusted odds ratio [aOR]=8. ^[2] The objective response rate was 44% (24 of 55 evaluable patients) for VIT versus 31% (18 of 58) for VI (adjusted odds ratio, 0. ^[3]

versus 20 %

Increasing levels of immunosuppression was associated with a reduced PFS (12-month PFS 62% no immunosuppression versus 49% oral steroids versus 33% IV steroids versus 20% further immunosuppressants, p = 0. ^[1] Younger firefighters were more likely to gain weight (53% versus 39%) and less likely (10% versus 20%) to lose weight as compared to older firefighters. ^[2] 9% versus 20%, 20% versus 35. ^[3]

% versus 25

During lockdowns, women reported increased time spent on hospital and laboratory tasks compared with men (53% versus 46% and 33% versus 26%, respectively) and a significantly higher proportion of women than men spent less time on science (39% versus 25%) and personal care (58% versus 39%). ^[1] 5%), SCSA (33% versus 25%) assays, chromatin maturity tests, CMA3 (58% versus 29%) and aniline blue (63% versus 35%) staining were higher in case sample compared to the fertile sample. ^[2] Les trois dispositifs étaient aussi méconnus des victimes avant confinement que des non-victimes : plateforme 3919 (34,3 % versus 31,9 %, p =0,38), Alerte pharmacie (44,5 % versus 41,3 %, p =0,28), SMS 114 (55,1 % versus 54 %, p =0,54) ; 0,6 % versus 0,4 % (p >0,99), 1,9 % versus 2,5 % (p =0,54) et 2,4 % versus 1,6 % (p =0,39) avaient découvert le 3919, l’Alerte pharmacie et le SMS 114 après le déconfinement. ^[3]

year overall survival

Patients with allo-HSCT showed superior 5-year overall survival (OS; 74% versus 38% or 49%; P <. ^[1] Five-year overall survival (OS ) and event-free survival EFS were significantly lower in children with DC than in children without DC (82 ± 5 % and 96 ± 1 %, respectively versus 37 ± 7 % and 62 ± 3 %, respectively). ^[2] 0 months, the 2-year overall survival was 89% in the HLA-matched group, versus 34% in the HLA-haploidentical group (P=. ^[3]

% versus 5

AMI‐IHO had a more severe clinical course with lower use of AMI therapies or invasive strategies and higher in‐hospital (7% versus 3%), 28‐day (19% versus 5%), and 1‐year (29% versus 12%) mortality (P<0. ^[1] Mutation frequencies for several genes were relatively higher in the HBV-positive patients than that in HBV-negative HCC patients, including TP53 (63% versus 39%), CCND1 (12% versus 5%), RB1(12% versus 4%) and BRCA2 (11% versus 4%). ^[2] The estimated rebleeding rates were 0% versus 5% at 3 months, 0% versus 11% at 6 months, 0% versus 18% at 1 year, and 0% versus 38% at 2 years after combined therapy and TIPS, respectively (P =. ^[3]

months p 0

0006), and 10 versus 3 months (p-0. ^[1] 8 months versus 30 months, p 0. ^[2]

% versus 12

Culture negativity after 6 months of treatment was similar for the decentralized sites compared to the national central site, 81% vs 79%, respectively, whereas decentralized sites had less loss to follow-up (0% versus 3%) and fewer deaths (3% versus 12%). ^[1] Asymmetric lacrimal gland enlargement (78% versus 13%), lack of frontal (0% versus 12%) or infraorbital nerve enlargement (0% versus 36%)were associated with OAL (all p<0. ^[2]

% versus 2

Severe toxicity include grade 3-4 leukopenia (4% versus 2%), neutropenia (20% versus 22%) , anemia (38% versus 34%), thrombocytopenia (18% versus 24%), neurotoxicity (2% versus 6%) with DD and DP, respectively. ^[1] Adjusted for age and race, women had more noncardiac causes of presumed SCD, including pulmonary emboli (8% versus 2%) and neurological causes (10% versus 3%, both P<0. ^[2]

% versus 18

Characteristics significantly associated with Lyme neuroborreliosis were headache (55% versus 18%), meningeal irritation (21% versus 5%), presentation in summer months (69% versus 37%), and a previous tick bite (33% versus 7%). ^[1] Patients treated with a staged approach experienced fewer intraoperative complications (0% versus 18%) and fewer revision surgeries (25% versus 36%). ^[2]

versus 10 %

More auto-HCT recipients were in complete response at HCT relative to allo-HCT recipients (66% versus 34%), while a higher proportion of allo-HCT recipients had 17p deletion (33% versus 7%) and had previously received novel agents (39% versus 10%). ^[1] In law states, Black MSM were more likely than White MSM to report their community would discriminate against persons with HIV (PWH) (59 versus 34%), not support the rights of PWH (20 versus 9%), not be friends with PWH (19 versus 10%), believe PWH 'got what they deserved' (27 versus 16%), and be intolerant of MSM (14 versus 5%). ^[2]

months 95 %

58) and achieved pregnancy earlier compared to those men with TPMC < 50 million (median 19 months (95% CI: 18-20) versus 36 months (95% CI: 32-41)). ^[1] 5 months (95% confidence interval [CI], 5-14 months) and the TTPL was 3 months (95% CI, 2-6 months) versus 33 months (95% CI, 22-39 months) and 23 months (95% CI, 7-38 months), respectively, for those with a tumor dose of 125 Gy or more (P = 0. ^[2]

% odds ratio

001) or ventilation (47% versus 32%, odds ratio 1. ^[1] The proportion of pregnant employees who had demanding occupational exposures, good psychosocial work environment and good well-being in the intervention versus the control group were 36% versus 39% (odds ratio (OR)=0. ^[2]

1 % respectively

1%, respectively, versus 38. ^[1] 1%, respectively, versus 38. ^[2]

versus 4 %

Results: Hip replacement median length of stay in our series was two nights versus five nights, inpatient rehabilitation 7% versus 36%, ICU admission zero versus 4%, and readmissions 3. ^[1]